Alx Oncology Holdings INC Schedule 13G passive stakes

TCG Crossover entities and Chen Yu have amended their Schedule 13G filing to reflect updated beneficial ownership of ALX Oncology Holdings Inc. common stock.

HBM Healthcare Investments (Cayman) Ltd. has filed an amendment reporting beneficial ownership of 6.5% of ALX Oncology Holdings Inc. common stock.

Millennium Management and affiliated entities report a 1.5% beneficial ownership stake in ALX Oncology Holdings Inc.

RA Capital Management and its affiliates have disclosed a 9.9% beneficial ownership stake in ALX Oncology Holdings Inc., totaling 13,117,106 shares.

TCG Crossover Funds and Chen Yu have disclosed a combined 9.9% beneficial ownership stake in ALX Oncology Holdings Inc. following a recent underwritten offering.

Tang Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in ALX Oncology Holdings Inc., now holding 0% of the common stock.

Tang Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in ALX Oncology Holdings Inc., now holding 0% of the common stock.

Millennium Management and affiliated entities, including Israel A. Englander, reported increasing their beneficial ownership in ALX Oncology Holdings Inc. to 6.0%.

Millennium Management LLC and affiliates have reported a 5.1% beneficial ownership stake in ALX Oncology Holdings Inc., signaling significant institutional interest.

Redmile Group, LLC and its affiliates disclosed continued significant beneficial ownership of 8.5% in ALX Oncology Holdings Inc. common stock.

Tang Capital Management, LLC and affiliated entities, including Kevin Tang, have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 5.9% in ALX Oncology Holdings Inc. as of March 31, 2025.

HBM Healthcare Investments (Cayman) Ltd. has filed an amended Schedule 13G, disclosing a beneficial ownership of 8.4% in ALX Oncology Holdings Inc. as of March 31, 2025.

Tang Capital Management, Kevin Tang, and Tang Capital Partners have jointly filed an amended Schedule 13G, reaffirming their beneficial ownership of 6.3% of ALX Oncology Holdings, Inc.'s common stock as of December 31, 2024.